Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Terminated 2Completed 2Withdrawn 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Other hematologic neoplasm 2Thoracic 1

Conditions

Leukemia, Promyelocytic, Acute 1Leukemia, Myeloid, Acute 1

Interventions

Cyclophosphamide 122Cytarabine 112fludarabine 91fludarabine phosphate 80Rituximab 75Azacitidine 74venetoclax 54Methotrexate 52Filgrastim 48Whole-Body Irradiation 45Busulfan 45Tacrolimus 35Etoposide 35Mycophenolic Acid 34Lenalidomide 32Imatinib Mesylate 32Antilymphocyte Serum 32Granulocyte Colony-Stimulating Factor 31Decitabine 31Peripheral Blood Stem Cell Transplantation 29Dexamethasone 29Cyclosporine 29Vincristine 26Melphalan 26Clofarabine 25Alemtuzumab 25Mitoxantrone 24Stem Cell Transplantation 22Radiotherapy 22Dasatinib 22

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Terminated × tamibarotene × Other hematologic neoplasm × Clear all
NCT04905407 2025-02-24

Tamibarotene Plus Venetoclax/Azacitidine in Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

Syros Pharmaceuticals

Phase 2 Terminated
66 enrolled 21 charts
Other hematologic neoplasm

Leukemia, Myeloid, Acute

NCT00985530 2013-10-30

Tamibarotene and Arsenic Trioxide for Relapsed Acute Promyelocytic Leukemia

Northwestern University

Phase 1 Terminated
4 enrolled
Other hematologic neoplasm

Leukemia, Promyelocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡